Orange Health Service, Orange, NSW, Australia.
Heart Lung Circ. 2020 Jul;29(7):964-972. doi: 10.1016/j.hlc.2020.05.004. Epub 2020 May 25.
Debate continues in the medical literature on the role of the renin angiotensin system (RAS) in Coronavirus disease 2019 (COVID-19) pathophysiology and the implications for the use of cardiovascular drugs acting on the RAS. Could these drugs - which include angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptors blockers (ARBs) - be harmful or potential key therapeutic agents in COVID-19? And, could potentially helpful measures be available and in plain view on the pharmacy shelf?
医学文献中一直存在争议,即肾素-血管紧张素系统(RAS)在 2019 年冠状病毒病(COVID-19)病理生理学中的作用,以及这些作用对心血管药物(作用于 RAS 的药物)的使用的影响。这些药物包括血管紧张素转换酶抑制剂(ACEIs)和血管紧张素受体阻滞剂(ARBs),它们在 COVID-19 中是有害的还是潜在的关键治疗药物?并且,在药店的货架上是否可以看到潜在的有用措施?